肿瘤免疫逃逸的艺术。
The ART of tumor immune escape.
机构信息
Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
Department of Cardiothoracic and Vascular Surgery, Albert Einstein College of Medicine, Bronx, NY, USA.
出版信息
Oncoimmunology. 2022 May 14;11(1):2076310. doi: 10.1080/2162402X.2022.2076310. eCollection 2022.
We recently identified the adenosine-5'-diphosphate (ADP)-ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R) on CD8 T cells, resulting in NAD-induced cell death (NICD) and tumor immune resistance. This process is blocked by therapeutic antibody targeting of ART1.
我们最近发现，腺嘌呤二核苷酸(ADP)-核糖基转移酶-1(ART1)是癌细胞表达的一种新的免疫检查点。ART1 在肿瘤微环境 (TME) 中利用游离烟酰胺腺嘌呤二核苷酸 (NAD) 对 CD8 T 细胞上的 P2X7 受体 (P2X7R) 进行单 ADP-核糖基化 (MARylation)，导致 NAD 诱导的细胞死亡 (NICD) 和肿瘤免疫抵抗。这一过程可被靶向 ART1 的治疗性抗体所阻断。
Zotero 插件